eribulin mesylate

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

HER2-normal

Conditions

HER2-normal

Trial Timeline

Mar 3, 2011 → Oct 19, 2017

NCT ID

NCT01328249

About eribulin mesylate

eribulin mesylate is a phase 2 stage product being developed by Eisai for HER2-normal. The current trial status is completed. This product is registered under clinical trial identifier NCT01328249. Target conditions include HER2-normal.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (19)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03441360	Phase 2	Completed	Apr 17, 2018	Jan 21, 2022	Relapsed/Refractory Rhabdomyosarcoma
NCT03583944	Approved	Completed	Mar 28, 2018	Jun 28, 2019	Breast Neoplasms
NCT03361436	Phase 1	Active	Mar 19, 2018	Apr 14, 2033	Liposarcoma
NCT03437083	Pre-clinical	Completed	Jan 25, 2018	Jun 30, 2018	Locally Advanced or Metastatic Breast Cancer
NCT03058406	Pre-clinical	Completed	Mar 1, 2016	Nov 4, 2018	Sarcoma, Soft Tissue
NCT02481050	Phase 2	Completed	Jun 16, 2015	Sep 5, 2017	Breast Cancer
NCT02338037	Phase 1	Completed	May 19, 2015	Mar 15, 2024	Metastatic Malignant Neoplasm in the Adult Brain
NCT02171260	Phase 1	Completed	Jul 31, 2014	Jan 28, 2016	Pediatrics
NCT03245112	Pre-clinical	UNKNOWN	Mar 3, 2014	Dec 31, 2017	Metastatic Breast Cancer
NCT01961544	Approved	Completed	Jun 1, 2013	Jul 1, 2015	Breast Neoplasms
NCT01458249	Phase 2	Completed	Nov 1, 2011	Feb 1, 2016	Soft Tissue Sarcoma
NCT01463891	Pre-clinical	Completed	Jul 19, 2011	Nov 27, 2013	Inoperable or Recurrent Breast Cancer
NCT01328249	Phase 2	Completed	Mar 3, 2011	Oct 19, 2017	HER2-normal
NCT01240421	Pre-clinical	Completed	Mar 1, 2011	Nov 1, 2014	Metastatic Breast Cancer
NCT01268150	Phase 2	Completed	Feb 1, 2011	Aug 1, 2013	Locally Recurrent
NCT01269346	Phase 2	Completed	Dec 1, 2010	May 1, 2016	Breast Cancer
NCT01142661	Pre-clinical	Completed	Aug 1, 2010	—	Breast Cancer
NCT01106248	Phase 1	Completed	Mar 1, 2009	—	Advanced Solid Tumor
NCT00965523	Phase 2	Completed	Jan 1, 2008	Jan 1, 2011	Breast Cancer

Other Products from Eisai

MecobalaminApproved

MonteplaseApproved

E2020 + PlaceboApproved

Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved

DonepezilApproved